Relentless for the Cures

2000 Annual Report

The Leukemia & Lymphoma Society™
Fighting Blood-Related Cancers

Our name

We added the word “lymphoma” to our name last year to bring into focus the full scope of our mission—fighting all hematological malignancies. The Society was further motivated by a startling rise in lymphoma incidence rates over the last two decades. For all these blood-related cancers, we have been, and will continue to be, relentless for the cures.
Status of blood related cancers:

Leukemia

We're winning the battle... The five-year survival rate for leukemia patients has tripled from 14% in 1960, to 44% in 1995. The five-year survival rate for children with acute lymphocytic leukemia is 81%.

But the war isn't over... This year in the U.S., an estimated 30,800 new cases of leukemia will be diagnosed, and approximately 21,700 people will die from the disease.

Lymphoma

We're winning the battle... The five-year survival rate for non-Hodgkin’s lymphoma patients rose from 31% in 1960 to 52% in 1995. In children, the five-year survival rate is 78%, a significant improvement in the last 30 years.

But the war isn't over... About 62,300 Americans will be diagnosed with lymphoma in 2000, the vast majority with non-Hodgkin’s lymphoma. An estimated 27,500 people will die from lymphoma in 2000, the majority from non-Hodgkin’s lymphoma.

Myeloma

We're making progress... The survival rate for myeloma is 28%, a modest improvement from 24% in the 1970s.

But there's much more we need to do... An estimated 13,600 new cases of myeloma will be diagnosed in the U.S. in 2000, and approximately 11,200 people will die from it.
Relentless for the Cures

Relentless for the cures. It means that nothing will stand in the way of those determined to carry out the Society’s mission. The record this year, as well as future plans, attest to this ongoing commitment.

Take a look at the Society’s research programs. The relentless pursuit of cures can be found, for example, in the promising therapy developed by Dr. Brian Druker to treat chronic myelogenous leukemia. All 31 patients treated in the initial clinical trials have had their blood counts return to normal, so the trials have expanded to more than 1,500 patients—and we are very optimistic.

Take a look at our new SCOR program (Specialized Center of Research), with $22.5 million targeted to three groups of scientists working cooperatively on a range of research to fight blood-related cancers. We expect to triple this program over the next few years.

In patient services, you’ll find “relentless” in the Information Resource Center programs—lifelines of emotional support and timely professional guidance for tens of thousands of patients. And through its web site and the Internet, the Society speeds the delivery of vital information and services, and engages patients and volunteers more efficiently. In a very real sense, the Internet is providing the Society with an increasing presence and greater capacity to expand the reach of its mission.

The supporters of the Society are also relentless about raising the money that fuels these programs, having increased the Society’s net revenue by 24% this year to a record $133.4 million. In fact, in terms...
of share of donations raised, the Society continues to be the fastest growing nationwide voluntary health organization in the U.S. How did we get there? Look at the national Light The Night® Walk campaign, which raised $5 million in fiscal year 2000 and nearly twice that amount this year. Or talk to people like Harry Pearce, Vice Chairman of General Motors, who is launching a personal campaign to raise millions of new dollars for research.

Of course, nothing says relentless more than Society volunteers—individuals, families and business owners, trustees at every chapter, and even renowned scientists who spend countless hours of “free” time assessing research proposals.

Today, more people are surviving blood-related cancers than ever before, but it’s not enough. With powerful new tools and a growing array of new programs and services, the volunteers and staff of the Society are truly relentless for the cures. Nothing will stand in their way.

Jay L. Silver
Chairman

Dwayne Howell
President and CEO

“”

The Society continues to be the fastest growing nationwide voluntary health organization in the U.S.

(1-r) Richard A. Fess, Peter J. Quesenberry, MD, Jay Silver, Dwayne Howell, W. Stratford May Jr., MD, PhD
Strengthening research—the SCOR grants

The Leukemia & Lymphoma Society’s new Specialized Center of Research (SCOR) Program will provide $22.5 million in research grants over five years, to three groups of outstanding scientists working on blood-related cancers.

In addition to the three grants designated for 2000-2001, the Society is committed to funding six more SCOR grants over the next three years, amounting to a total of $67.5 million in team-based research.

These grants are designed to bring together programs that share a common research focus and attack the same scientific problems. With scientists from different disciplines working in concert, the research community will have a better chance to develop cures and achieve significantly higher survival rates.

The SCOR at Weill Medical College of Cornell University will focus on myeloma, an incurable cancer of the antibody-producing plasma cells. The team will work to understand the genetic basis of this cancer, control the accumulation of malignant cells and prevent bone destruction caused by the myeloma.

The SCOR at Dana-Farber Cancer Institute will concentrate on developing curative therapies for acute and chronic myelogenous leukemias by providing ways to translate laboratory research into novel approaches for diagnosis and treatment.

How you can help

• Support research programs by volunteering with the Society
• Raise and contribute funds for research
The SCOR at Oregon Health Sciences University, in collaboration with scientists at the M.D. Anderson Cancer Center and the University of California at Los Angeles, will focus on chronic myelogenous leukemia (CML) and a compound known as STI-571, which has had remarkable success in putting CML patients into remission in recent clinical trials. This center will work to determine the causes of CML and how to best use STI-571 as a treatment.

“Scientists from different disciplines working together will have a better chance to develop cures and achieve higher survival rates.”

Marshall Lichtman, MD, congratulates SCOR awardees (l-r): James D. Griffin, MD, Dana-Farber Cancer Institute; Selina Chen-Kiang, PhD, Weill Medical College, Cornell University; Brian J. Druker, MD, Oregon Health Sciences University
Thanks to the Society’s research efforts, the survival rate for children with acute lymphocytic leukemia is 81%.
The Career Development Program provides funding for the most promising young scientists. Currently, the Society supports 129 Fellows and 153 Special (advanced) Fellows who work with outstanding senior scientists to uncover the mysteries of the genes, molecules, and aberrant cell systems that lead to blood-related cancers.

In addition, 88 Scholars are supported by the Career Development Program. These scholars are young, independent scientists bringing the most recent technologies and new ideas to the laboratory. To further translate gains in basic knowledge to an increase in cure rates, the Society also initiated a variation of its Scholar Program, known as Scholars in Clinical Research. Since it began three years ago, this program has funded 13 scientists.

Recognizing that the movement of basic research to clinical application is the final pathway to cures, the Society also continues to expand its Translational Research Program. The funding of research on STI-571 in the treatment of chronic myelogenous leukemia (CML) is an example of the Society’s investment in new and promising translational research.

In fiscal 2000, 131 Translational grants were supported, offering potentially new approaches to chemotherapy, immunotherapy, and stem cell transplantation.
Extending our reach to patients and communities

Support, understanding and knowledge—they go a long way to help patients battle blood-related cancers. Nowhere are these qualities more concentrated and effective than in the Society’s expanding array of patient and community service programs.

From conducting Family Support Groups to helping children make a smooth transition from treatment back to school, the Society is deeply committed to reaching every patient and family with services that improve their lives.

In 2000, for example, the Society’s Information Resource Center (1-800-955-4572) connected more than 35,000 patients, caregivers and healthcare professionals to the IRC’s skilled nurses and social workers. The IRC staff provides timely information and referrals, including data on diagnoses, treatment options and clinical trials, as well as guidance on second opinions and counseling.

For the newly diagnosed patient, First Connection is a lifeline to a trained peer who understands the feelings and needs first-hand. In 2000, more than 2,200 individuals took advantage of this service, a figure that is expected to increase substantially.

Through a collaboration with the National Coalition for Cancer Survivorship, and supported by an educational grant from Ortho Biotech, the Society offers “Cancer: Keys to Survivorship,” a seminar providing empowering information and tools. Participants learn about communicating effectively with healthcare providers, strategies for self-empowerment and self-care, obtaining and collecting health insurance benefits, and employment rights issues.

A new educational symposium also aimed at assisting patients is “Improving the Chemotherapy Experience.” Supported by Amgen, Inc., ICE is designed to help chemotherapy patients help themselves physically and emotionally through the challenge of treatment.

Hildy Dillon (standing), Senior Director, Information Resource Center; Tammi Haber, Senior Specialist, Health Care Navigation
The Society is deeply committed to reaching every patient and family with services that improve their lives.

How we help

• By providing a targeted series of psychosocial and practical services
• By supporting patients, from diagnosis through treatment and recovery
Increasing our influence through advocacy

With almost 3,000 volunteers, the Society’s Advocates Network is a powerful voice on behalf of patients, speaking out to legislators and other government leaders on such issues as medical research funding, insurance coverage and access to care.

As a result, many Members of Congress have become engaged in Society programs and have gained a greater appreciation of the Society’s goals and the role they can play in achieving them.

After several years of legislative appeals by Society advocates, President Clinton announced on June 7 that Medicare would begin covering the routine care costs of clinical trials, including meals, beds and nursing services.

With the helpful prodding of Society advocates, the National Cancer Institute initiated a Progress Review Group on blood-related cancers, which includes Society members, to help look for promising new research opportunities that the NCI could support.

Meanwhile, the Society continues to forge alliances with various groups in order to strengthen its hand with policymakers. As part of the National Health Council, the Cancer Leadership Council, One Voice Against Cancer and The Independent Sector, the Society exerts a stronger influence on issues of common interest.

Looking ahead, the Society’s Public Policy office in Washington has been strengthened to help volunteers keep up with legislative developments and facilitate swift and targeted action. The Society’s web site and its Legislative Action Center are part of this effort. New recruitment materials and issue briefs, a stronger training curriculum and a broader policy agenda have also been designed to engage and mobilize volunteer-advocates.

Legislators and government officials are gaining a greater appreciation of their role in helping the Society achieve its goals.

President Clinton recognizes Leukemia and Lymphoma Awareness Month (September) in the Oval Office with Society President and CEO Dwayne Howell and several young patients.
How you can help

• Join the Society’s Advocates Network
• Learn about legislative issues affecting patients
• Help speak out for patients and their families
• Keep up with developments on Capitol Hill
• Respond to "calls-to-action" by contacting legislators and expressing your concern about important issues
Growing our revenue base

Cures can be found only with more research. More research can take place only with more revenue. And so, the Society has been relentlessly growing its revenue base, which increased by 24% in 2000.

Through Team In Training®, the Society’s largest fundraising effort, volunteers raise funds running, walking, cycling and swimming, as they train to participate in prestigious endurance events.

The Light The Night® Walk is another dynamic fundraising and awareness campaign. In its second year as a national event, Light The Night was held at over 170 sites in September 2000, up from 100 in 1999. Result: revenues nearly doubled.

Other grassroots events that are growing significantly include the School & Youth™ Programs. Through such programs as “Pasta for Pennies” sponsored by Olive Garden Restaurants, “Pennies for Patients” and “Hop for Leukemia,” school children raised nearly $9 million in fiscal 2000, while reaping the personal reward of helping people.

Meanwhile, major gifts from individuals, corporations and foundations continue to be a vital source of support. Harry Pearce, Vice Chairman of General Motors, is taking his own successful battle with leukemia from the hospital to the boardroom. Not only is GM leading the way with a $1.5 million grant for the SCOR program, but Mr. Pearce is launching a personal crusade to raise millions of new research dollars with his Journey of Hope Major Gift.
How you can help

• Make a personal gift to the Society
• Become a participant and enlist your business or employer in Light The Night® Walk
• Take on the challenge of Team In Training®
• Volunteer for fundraising events through your local Society chapter
• Include the Society in your will
• Make a donation in the name of someone you love

Campaign. Also joining the crusade are Tom and Sandy Bertelsen of California. The Bertelsens are supporting a SCOR project led by Dr. Brian Druker, which focuses on finding cures for CML.

Net Revenue Growth 1996-2000 (in millions)

(l-r) David S. Dimling, Chairman, Fundraising Committee; Richard J. Geswell, Senior Vice President, Revenue Development
How you can help

• Participate in one of the Society’s major events through your local chapter
• Make a contribution when you receive direct response fundraising materials
• Speak out about the good work of the Society to your friends and neighbors
In the public relations arena, the Society is contacting leading medical and scientific writers and reporters about the volume and nature of Society-funded research and patient services. The focus in 2000 is on the new Specialized Center of Research (SCOR) Program, which generates interest as significant news and builds a foundation for ongoing media relations.

Meanwhile, the Society reached more than 18 million households and small businesses through a campaign of direct mail, telemarketing, neighborhood drives and e-marketing. In addition to raising funds, these campaigns inform the public about blood-related cancers and Society programs.

Media events also help spread the word to millions of people while raising funds. Annual events include syndicated talk show host Rush Limbaugh’s annual radio campaign, and the “Chase to the Cure” television special, broadcast in New York on WPIX-TV and sponsored by Chase Manhattan Bank. In Fall 2000, new public service announcements featuring celebrity Cindy Crawford, a trustee of the New York City Chapter, also began hitting the airwaves around the country.

Advertising and promotions supporting major Society events also go a long way to increase participation and enhance awareness. Ads in national magazines helped to draw nearly 30,000 participants for Team In Training®, and public service announcements on TV reached millions of viewers. Light The Night® Walk drew nearly 50,000 participants, and millions of people to the Society’s Light The Night Walk message, thanks to related magazine and internet ads and web site hits.
Advancing our mission through volunteer-staff partnership

The dynamic partnership between volunteers and staff is a critical element in advancing the Society's mission. Volunteers—from the national board and local trustees, to scientists contributing their time and talents to identify the most promising research, to local event organizers and participants—bring passion and enthusiasm in all they do.

Without volunteers, the Society's relentless pursuit of cures for blood-related cancers would be stopped cold. Meanwhile, the staff provides the support and technical expertise to volunteers, which result in high-quality and productive programs and events.

At all 58 chapters, volunteer trustees join staff to provide the leadership, strategic planning, community organizing and recruitment skills to achieve the Society's goals. This past year, new guidelines were introduced to challenge trustees to make the highest impact possible—in accessing resources in their communities, advancing the Society's mission, and ensuring the ongoing health and productivity of the organization.

Only with high-impact boards, working in conjunction with staff, can the job of attracting, training and mobilizing tens of thousands of volunteers be accomplished. These are the people who organize events, answer phones, support healthcare

How you can help

- Volunteer at your local Society chapter
- Help to recruit other volunteers
- Recommend community leaders to serve as chapter trustees
- Participate in local programs and events
professionals in patient service programs, advocate for research funding to state and local officials, and reach out to the community in innumerable ways.

The volunteer-staff partnership fuels the Society’s mission, enabling everyone to work better and smarter to advance the Society’s relentless quest to find cures for all blood-related cancers.

“The volunteer-staff partnership fuels the Society’s mission to find cures for all blood-related cancers.”

(l-r) Paul Weiss, Senior Vice President, Chapter Development; Lynn C. Hoover, Chairman, Chapter Development Committee
Building a stronger team for the future

People who work for The Leukemia & Lymphoma Society know they are making a difference in the battle against blood-related cancers. It’s not just a job, but a passionate commitment.

To make sure everyone is working as effectively and efficiently as possible, the Society continues to strengthen its infrastructure and foster a team-based environment that motivates both staff and volunteers alike.

This year’s Home Office move to White Plains, New York, for instance, helps to meet those objectives by optimizing office space while minimizing costs, enhancing recruitment efforts and centralizing on-site training—so that staffers and volunteers from around the country can reap the benefit of face-to-face interactions with colleagues.

Training, networking and recognition programs are also key components of building a stronger team. The Annual Leadership Conference and the Annual Professional Conference, for example, enable regional and chapter leaders, key staff and volunteers to learn, share ideas, and reward excellence, so they can meet their respective challenges refreshed and motivated.

The Internet opportunity

Nothing, however, will be a greater team-building tool than the Internet. Already in 2000, more than a million people contacted the Society through its web site, a number that’s expected to triple in the next year.

With new Internet capabilities coming on line in early 2001, the Society’s web site will be an even more dynamic resource, reaching, engaging and delivering individualized services to millions of people immediately—any time, anywhere. For patients, their families, volunteers, healthcare professionals, donors and others, the site will offer high levels of interaction, customization, rich content and links to chapters and other relevant sites.
When a visitor provides an e-mail address and a profile of interest, the Society will be able to offer that visitor an individualized “home page” for receiving the latest information, program updates and clinical news that match his or her specific needs. This capability will empower patients, for example, with the latest medical information and guidance to ensure the best treatment for their disease.

The visitor’s home page will also be able to archive pertinent video presentations, teleconferences and other educational sessions. Additionally, the web site will offer online registration and instruction, and direct support to those who want to participate in advocacy, fundraising and other programs that strengthen the Society’s mission.

For chapter offices, these new capabilities will provide a centralized, “turnkey” infrastructure. With a simple PC and Internet access, chapters will be fully connected to the rest of the organization, yet be able to tailor web site information on their activities and events.

How you can help

- Find out about career opportunities at the Society
- Get comfortable with the Internet
- Promote the use of information technology
- Explore the Society’s website and refer others to it
Research grants—SCOR and Career Development Program

Specialized Center of Research ¹
Selina Chen-Kiang, PhD - 2000
Weill Medical College of Cornell University
Brian J. Druker, MD - 2000 ²
Oregon Health Sciences University
James D. Griffin, MD - 2000
Dana-Farber Cancer Institute

Career Development Program—Scholars
Paul J. Anderson, MD - 1995
Brigham and Women's Hospital
Donald E. Aver, PhD - 1998
University of Utah
Ravi Basavappa, PhD - 1999
University of Rochester
Timothy W. Behrens, MD - 1997
University of Minnesota
Mark Boothby, MD, PhD - 1995
Vanderbilt University School of Medicine
Katherine Borden, PhD - 2000
Mount Sinai School of Medicine
Emery H. Bresnick, PhD - 1997
University of Wisconsin Medical School
Stephen Buratowski, PhD - 1999
Harvard Medical School
Frederic D. Bushman, PhD - 1996
Salk Institute for Biological Studies
Don Chen, PhD - 2000
University of Massachusetts Medical School
Genhong Cheng, PhD - 2000
University of California, Los Angeles
Jonathan Chernoff, MD, PhD - 1997
Fox Chase Cancer Center
K. M. Coggeshall, PhD - 1998
Oklahoma Medical Research Foundation
Alan D. D'Andrea, MD - 1995
Dana-Farber Cancer Institute
George O. Daley, MD, PhD - 1999 ³
Whitehead Institute for Biological Research

¹ The Special Center of Research Grant Program is supported in part by a generous gift from General Motors Foundation.
² The Special Center of Research Grant of Dr. Brian J. Druker is funded in part by a generous gift from The Bertelsen Family.
³ Dr. Daley, a Stephen Birnbaum Scholar, is funded by a generous gift to the Society from The Stephen Birnbaum Foundation.

James A. DeCaprio, MD - 1997
Dana-Farber Cancer Institute
James DeGregori, PhD - 2000
University of Colorado Health Sciences Center
Laurence C. Eisenlohr, VMD, PhD - 1999
Thomas Jefferson University
Mark E. Ewen, PhD - 1997
Dana-Farber Cancer Institute
Carolyn A. Félix, MD - 1996
Children's Hospital of Philadelphia
Alan Patrick Fields, PhD - 1995
University of Texas, Galveston
Susan L. Forsburg PhD - 1997
Salk Institute for Biological Studies
Alan D. Friedman, MD - 1998
Johns Hopkins University School of Medicine
Xiang-Dong Fu, PhD - 1997
University of California, San Diego
Peter M. Glazer, MD, PhD - 1996
Yale University
Michael J. Grusby, PhD - 1997
Harvard School of Public Health
Wendy L. Havran, PhD - 1996
The Scripps Research Institute
Phillip W. Hinds, PhD - 1995
Harvard Medical School
Jae Jung, PhD - 2000
Harvard Medical School
Anthony N. Imbalzano, PhD - 1999
University of Massachusetts Medical Center
Y. Tony Ip, PhD - 1996
University of Massachusetts Medical Center
Mark P. Kamps, PhD - 1997
University of California, San Diego
Nigel Killeen, PhD - 2000
University of California, San Francisco
Michael Koelle, PhD - 1999
Yale University
Sally Kornbluth, PhD - 1998
Duke University Medical Center
David Lambright, PhD - 1998
University of Massachusetts Medical Center
Hyam I. Levitsky, MD - 1997
Johns Hopkins University School of Medicine
Daniel I. Lew, PhD - 2000
Duke University Medical Center
Jonathan D. Licht, MD - 1995
Mount Sinai School of Medicine
Paul Lieberman, PhD - 1997
The Wistar Institute
Hsiou-Chi Liou, PhD - 2000
Weill Medical College of Cornell University
Richard M. Longnecker, PhD - 1995 ⁴
Northwestern University School of Medicine
Kun Ping Lu, MD, PhD - 1998
Beth Israel Deaconess Medical Center
Richard S. Mann, PhD - 1997
Columbia University Health Sciences
Garry P. Nolan, PhD - 1995
Stanford University School of Medicine
Giuseppina Nucifora, PhD - 1998
Loyola University of Chicago
Matthew J. O'Connell, PhD - 2000
Dana-Farber Cancer Institute
Marjorie Oettinger, PhD - 1996
Susan L. Forsburg, PhD - 1997
Columbia University Health Sciences
Gerald Siu, PhD - 2000
Boston Medical Center

² Dr. Longnecker is supported in part by generous gifts to the Society from the Bernard Rachmilewitz Scholarship Foundation and the Helen V. Brach Foundation.
³ Dr. Pandolfi is supported by a generous gift to the Society from The Reichman Memorial and The Althaus Foundation.
⁴ Dr. Ron, a Stephen Birnbaum Scholar, is funded by a generous gift to the Society from The Stephen Birnbaum Foundation.
⁵ Dr. Ron, a Stephen Birnbaum Scholar, is funded by a generous gift to the Society from The Stephen Birnbaum Foundation.
Research grants—Career Development Program

Linda S. Huang, PhD – 1999
University of California, San Francisco

David Ching Siang Huang, MD – 1998
The Walter and Eliza Hall Institute

Paul Hughes, D Phil – 1997
The Scripps Research Institute

Jorge A. Higuera-Luhi, PhD – 1997
University of California, San Francisco

Bryan A. Irving, PhD – 1999
University of California, San Francisco

Feng Jiang, PhD – 1997
Memorial Sloan-Kettering Cancer Center

Jin Jiang, PhD – 1998
University of California, San Diego

Sepideh Khorasanizadeh, PhD – 1998
The Rockefeller University

Richard Klinghoffer, PhD – 2000
University of California, San Francisco

Fred Hutchinson Cancer Research Center

Jae Bum Kim, PhD – 1999
Duke University Medical Center

Stephen Jung, PhD – 1999
Skirball Institute

Kenneth B. Kaplan, PhD – 1997
Massachusetts Institute of Technology

Mark H. Kaplan, PhD – 1997
Indiana University

Barbara L. Kee, PhD – 1998
University of North Carolina, Chapel Hill

Sepideh Khorasanizadeh, PhD – 1998
HHMI, University of Maryland

Unkyu Kim, PhD – 1998
The Rockefeller University

Jae Bum Kim, PhD – 1999
Massachusetts Institute of Technology

Keiji Kimura, PhD – 1997
Cold Spring Harbor Laboratory

David T. Kirkpatrick, PhD – 1998
Case Western Reserve University

Richard Klinghoffer, PhD – 2000
Fred Hutchinson Cancer Research Center

Anthony J. Koleske, PhD – 1997
Yale University

Keith J. Kozminski, PhD – 1999
University of California, Berkeley

Dr. Irving is supported by a generous gift to the Society from the Board of Trustees and Staff, Northern California Chapter.

Dr. Kozminski is supported in part by a generous gift to the Society from the Wayne & Gladys Valley Foundation.

Dr. Lee is supported by a generous gift to the Society from The Hildegarde D. Becher Foundation.

Dr. Richardson is supported by a generous gift to the Society from Parents Against Leukemia.

Dr. Satterthwaite is supported in part by a generous gift to the Society from Parents Against Leukemia.

Anne Satterthwaite, PhD – 1998
HHMI, University of California, Los Angeles

Brian Shafer, PhD – 2000
National Jewish Medical & Research Center

Clemens A. Schmitt, PhD – 2000
Cold Spring Harbor Laboratory

Brenda A. Schulman, PhD – 2000
Memorial Sloan-Kettering Cancer Center

Joachim L. Schultz, MD – 1998
Dana-Farber Cancer Institute

Jae Hong Seol, PhD – 2000
California Institute of Technology

Thomas L. Serano, PhD – 2000
University of California, Berkeley

Kai-ichi Shabahara, PhD – 2000
Cold Spring Harbor Laboratory

Caroline E. Shamu, PhD – 1998
Harvard Medical School

Virginia Smith Shapiro, PhD – 1998
HHMI, University of California, San Francisco

Robert Joseph Sheaff, PhD – 1997
University of Minnesota

Wu-Cheng Shan, PhD – 1998
University of Massachusetts Medical Center

Hyun Suk Shim, PhD – 1998
Johns Hopkins University School of Medicine

Protul A. Shrikant, PhD – 2000
Roswell Park Cancer Center

Julia Sidorova, PhD – 1999
Fred Hutchinson Cancer Research Center

David A. Sinclair, PhD – 1999
Cold Spring Harbor Laboratory

Maria S. Soengas, PhD – 1999
Cold Spring Harbor Laboratory

Lisa N. Spirio, PhD – 1998
Whitehead Institute

Charles H. Spruck III, PhD – 1999
The Scripps Research Institute

Srinivasa M. Srinivasula, PhD – 2000
Kimmel Cancer Center

Dr. Satterthwaite is supported in part by a generous gift to the Society from Parents Against Leukemia.

Dr. Satterthwaite is supported in part by a generous gift to the Society from Parents Against Leukemia.
20 Dr. Stanford is supported by a generous gift to the Society from The Karlyn Glick Research Fund.

21 Dr. Chen is supported by a generous gift to the Society from The Valley Foundation.
Ann Kelly, PhD - 2000
American Red Cross

Brian Kennedy, PhD - 1997
Massachusetts General Hospital

Andrei V. Khokhlatchev, PhD - 1999
Massachusetts General Hospital

Chang H. Kim, PhD - 1999
Stanford University

Tae-Hyoung Kim, PhD - 2000
University of Pittsburgh School of Medicine

Tatiana V. Kolesnikova, PhD - 1999 24
Dana-Farber Cancer Institute

Rhett Kovall, PhD - 2000
Columbia University Health Sciences

Yuem Yu Amy Lam, PhD - 1998
Johns Hopkins University School of Medicine

Douglas V. Laurents, PhD - 1997
Instituto de Estructura de la Materia

Bee-Na Lee, PhD - 1997
Harvard Medical School

Sang Eun Lee, PhD - 1997
Brandeis University

Bibo Li, PhD - 1998
The Rockefeller University

Jianze Li, PhD - 1999
Harvard Medical School

Yong Li, PhD - 1998
HHMI, California Institute of Technology

Monika Lijedahl, MD, PhD - 1999
University of California, San Diego

Young-Mi Lim, PhD - 1998
University of California, Los Angeles

Kuo-I Lin, PhD - 1999
Columbia University Health Sciences

Meei-Yun Lin, PhD - 2000
University of California, San Diego

Jinli Liu, MD, PhD - 1999
Yale University School of Medicine

David Loeb, MD, PhD - 2000
Johns Hopkins University School of Medicine

23 Dr. Kim is funded by a generous gift from the Society from Delora Sanfilippo in memory of Hank Marine and Bob Staufler.

24 Dr. Kolesnikova is supported in part by a generous gift to the Society from the Family of Anne Rodin, in her memory.

Pei-Jung Lu, PhD - 1999
Beth Israel Deaconess Medical Center

Biao Luo, PhD - 1999
Whitehead Institute

Bart Lutterbach, PhD - 1998 25
Vanderbilt University

Erik Martinez-Hackett, PhD - 1998 26
HHMI, Columbia University

Lori F. Maxfield, PhD - 1998
Tufts University School of Medicine

Catherine J. McMahon, PhD - 1998
University of Washington

Taha Merghoub, PhD - 1999
Memorial Sloan-Kettering Cancer Center

Nadeem Moghal, PhD - 1998
HHMI, California Institute of Technology

Shivani Nautiyal, PhD - 1999
University of California, San Francisco

Erik Nelson, PhD - 2000
Beth Israel Deaconess Medical Center

Yael Nevo-Caspi, PhD - 1999
Tel-Aviv University

Ichiko Nishijima, PhD - 2000
Baylor College of Medicine

Clodagh O’Shea, PhD - 1999
University of California, San Francisco

Koshi Oishi, MD, PhD - 1999
Fred Hutchinson Cancer Research Center

Paula M. Oliver, PhD - 1999
National Jewish Medical & Research Center

Kay Keger Opperman, PhD - 1999
Johns Hopkins University School of Medicine

Gabriela C. Perez-Alvarado, PhD - 1997
The Scripps Research Institute

Toni Portis, PhD - 1999
Washington University School of Medicine

Kiley Prilliman, PhD - 2000
La Jolla Institute for Allergy and Immunology

Joe Ramos, PhD - 1997
The Scripps Research Institute

25 Dr. Lutterbach is supported by a generous gift to the Society from The John and Shirley Davies Foundation.

26 Dr. Martinez-Hackett is supported by a generous gift to the Society from the Jane Elissa/Charlotte Meyers Fund.

Hai Rao, PhD - 1998
California Institute of Technology

Karyme M. Reilly, PhD - 1997
Harvard University

Stephanie Anne Richards, PhD - 1998
Harvard Medical School

Celeste Jeanne Richardson, PhD - 1999 27
Harvard Medical School

Stephanie E. Rieder, PhD - 1999
The Scripps Research Institute

Shrikesh Sachdev, PhD - 1999
Ludwig-Maximilians University

Thomas Schindler, Dr Rer Nat - 2000
The Rockefeller University

Catherine A. Schnabel, PhD - 1998 28
Stanford University School of Medicine

Roger Sciammas, PhD - 1998 29
Stanford University School of Medicine

JoAnn M. Sekiguchi, PhD - 1998 30
Children’s Hospital Boston

Bart Lutterbach, PhD - 1998
HHMI, California Institute of Technology

Nadeem Moghal, PhD - 1998
HHMI, Columbia University

Andrei V. Khokhlatchev, PhD - 1999
HHMI, California Institute of Technology

Brian Kennedy, PhD - 1997
Brigham and Women’s Hospital

Susheela Tridandapani, PhD - 2000
Ohio State University

Chainerang Tunyaplin, PhD - 1997
Columbia University Health Sciences

Indira Unnikrishnan, PhD - 1999
Tufts University School of Medicine

Kirsten K. Walker, PhD - 1997
The Salk Institute for Biological Studies

Pablo Wappner, PhD - 1997
Weizmann Institute of Science

Tetsuro Watabe, PhD - 1998
University of California, Los Angeles

Julie Wilson-Annan, PhD - 1999
The Walter and Eliza Hall Institute

Catherine A. Wolkow, PhD - 1998
Massachusetts General Hospital

Dong Yu, PhD - 2000
Princeton University

Jinsong Zhang, PhD - 2000
Columbia University

Scott Tibbetts, PhD - 2000
Washington University School of Medicine

Michael Tomasson, MD - 1997
Brigham and Women’s Hospital

Ann Kelly, PhD - 2000
American Red Cross

Benjam...
Research grants—Translational Research Program

Robert Arceci, MD, PhD - 1997
Children's Hospital Medical Center

David W. Bahier, MD, PhD - 1998
University of Pittsburgh

Albert Baldwin, PhD - 1997
University of North Carolina, Chapel Hill

Edward D. Ball, MD - 1996
University of California, San Diego

Deborah E. Banker, PhD - 1998 33
Fred Hutchinson Cancer Research Center

Peter Leif Bergagel, MD - 1998 34
Well Medical College of Cornell University

Timothy Bestor, PhD - 1998 34
Fred Hutchinson Cancer Research Center

Ravi Bhatia, MD – 1999
University of Pittsburgh

Michael Boyer, MD – 1999
Columbia University Medical Sciences Center

Robert P. Castleberry, MD – 1998
University of Alabama, Birmingham

John Colicelli, PhD – 1997
University of California, Los Angeles

Kun-Sang Chang, PhD - 1998
University of Texas, Houston

Curt L. Civin, MD - 2000
Johns Hopkins University School of Medicine

David Claxton, MD - 1997
University of Texas, Houston

John Colicelli, PhD - 1997
University of California, Los Angeles

Els Goulmy, PhD - 1996
Leiden University Hospital

Steven Grant, MD - 1996, 2000
Virginia Commonwealth University

Timothy C. Greiner, MD - 2000
University of Nebraska Medical Center

30 Dr. Druker is supported in part by a generous gift to the Society from The Gold-Diggers.
31 Dr. Drucker is supported in part by a generous gift to the Society from The Stephen Birnbaum Foundation.
32 Dr. Goulmy is supported by a generous gift to the Society by The Gold-Diggers.
33 Dr. Bestor's grant is funded by proceeds from the Westchester/Hudson Valley Chapter Annual Ball.
34 Dr. Banker is funded by a generous gift to the Society from The Chuck Griffin Memorial Research Program.
35 Dr. Doek is supported by a generous gift to the Society from The St. Valentine's Day Luncheon & Style Show.
36 Dr. Drucker is supported in part by a generous gift to the Society from the Northwestern Mutual Foundation, Inc.
37 Dr. Gold is supported by a generous gift to the Society by KEYS.
38 Dr. Hnatyszyn is supported in part by a generous gift to the Society by The Stephen Birnbaum Foundation.
39 Dr. Kay is supported by a generous gift to the Society from The Stephen Birnbaum Foundation.
Hector Martinez-Valdez, MD, PhD - 1998
University of Texas, Houston

W. Stratford May, Jr., MD, PhD - 1998
University of Florida College of Medicine

Mark Minden, MD, PhD - 1999
Ontario Cancer Institute

Ramzi Mohammad, PhD - 1996 41
Wayne State University

Jefrey Molldrem, MD - 1998
University of Texas, Houston

Richard L. Monparler, PhD - 2000
Hôpital Sainte-Justine

Tuna Mutis, MD, PhD - 1999
Leiden University Medical Center

Robert S. Negrin, MD - 1998
Stanford University School of Medicine

Giuseppina Nuchitlora, DSc, PhD - 1999
Loyola University of Chicago

Robert Zygmunt Orlowski, MD, PhD - 1998
University of North Carolina, Chapel Hill

Lawrence Panasci, M.D. - 1998
Lady Davis Institute for Medical Research

Linda Z. Penn, PhD - 1998
Ontario Cancer Institute

Sharon E. Plon, MD, PhD - 1998
Baylor College of Medicine

Joseph Prchal, MD - 1997
University of Alabama, Birmingham

Shahin Rafii, MD - 2000
Weill Medical College of Cornell University

S. Vincent Rajkumar, MD - 1999
Mayo Clinic

Mariusz Z. Rabajczak, MD, PhD - 1999
University of Pennsylvania

Robert L. Redner, MD - 1999
University of Pittsburgh

Yair Reisner, PhD - 1998
Weizmann Institute of Science

Benjamin E. Rich, PhD - 2000
Brigham and Women's Hospital

Alain Rook, MD - 1997
University of Pennsylvania

Steven T. Rosen, MD - 1999 42
Northwestern University

Joseph Rosenblatt, MD - 2000
University of Rochester

Leona Samson, PhD - 1998
Harvard School of Public Health

Daniela Santoli, PhD - 1998
The Wistar Institute

Mathias Schmid, MD - 2000
University of Ulm

Joachim L. Schultz, MD - 1999
Dana-Farber Cancer Institute

Paul Schwarzenberger, MD - 1997
Louisiana State University Medical Center

Paul Shami, MD - 1997, 2000
University of Utah

Margaret A. Shipp, MD - 1997, 2000
Dana-Farber Cancer Institute

Donald Small, MD, PhD - 2000
Johns Hopkins University School of Medicine

Roger Stair, MD, PhD - 2000
University of Medicine & Dentistry of New Jersey

Richard A. Steinman, MD, PhD - 1998
University of Pittsburgh School of Medicine

Jeffrey W. Taub, MD - 1997
Wayne State University

Daniel G. Tenen, MD - 2000
Beth Israel Deaconess Medical Center

Nelson Teng, MD, PhD - 1997
Stanford University School of Medicine

Helan Tighe, PhD - 1999 43
University of California, San Diego

Fatih M. Uckun, MD, PhD - 1998
Wayne Hughes Institute

Jonathan Uhr, MD - 1997
University of Texas, Dallas

Marcel R.M. van den Brink, MD, PhD - 2000
Memorial Sloan-Kettering Cancer Center

Frits van Rhee, MD, PhD - 2000
Palmetto Richland Memorial Hospital

Ellen S. Viertel, PhD - 1997, 2000
University of Texas, Dallas

Edmund Waller, MD, PhD - 1997
Emory University

Paul Weiden, MD - 2000
Virginia Mason Research Center

Bruce Weinberg, MD - 2000
Duke University Medical Center

Peter W. Wiernik, MD - 1998
New York Medical College

Qing Yi, MD, PhD - 1999
University of Arkansas

James W. Young, MD - 1998
Memorial Sloan-Kettering Cancer Center

Alice L. Yu, MD, PhD - 1998 44
University of California, San Diego

John Yu, MD, PhD - 1997
The Scripps Research Institute

Xue-Zhong Yu, MD - 1999
Fred Hutchinson Cancer Research Center

Lisha Zhang, MD, PhD - 1999
University of Texas, Houston

41 Dr. Mohammad is supported in part by a generous gift to the Society from the Jim Jacobs Leukemia Research Fund.

42 Dr. Rosen is supported by a generous gift to the Society from the Dr. Ralph & Marion Falk Medical Research Trust.

43 Dr. Tighe is funded by a generous gift to the Society from The Chuck Griffin Memorial Research Program.

44 Dr. Yu is supported by a generous gift to the Society by KEYS.
Donors

Research

$1,000,000 and above
United Food & Commercial Workers
International Union

$100,000-$499,999
The Stephen Birnbaum Foundation
John and Shirley Davies Foundation
Ralph & Marian Falk Medical Research Trust
Glaxo Wellcome Foundation
Glaxo Wellcome Inc.
The Karyn Glick Special Fellowship
Quality Food Centers/Chuck Griffin Memorial Research Program
Carl Rosen Translational Research Fund

$50,000-$99,999
Charities 2000
Hildegard & De Becher Foundation, Inc.
Jane Elyssa/Charlotte Meyers Fund
Pete Harman
Jim Jacobs Leukemia Research Fund
Delora Sanfilippo
Dr. Scholl Foundation
Harold Simmons Memorial Golf Tournament

$10,000-$49,999
Alabama Power Company
American Airlines
In Memory of Dr. Jerry Anderson
Hampton Ansley Research Fund
The Beasley Foundation
The Berner Charitable and Scholarship Foundation
Baker Botts
Helen V. Brach Foundation
The Breen-Adams Foundation
Cadillac Plastics
The Gail Cohen Leukemia Fund
The Coleman Foundation
Mr. Raymond M. Dunning, Jr.
Mr. and Mrs. Craig Evans
Mr. and Mrs. Fred Fischer
The Richard D. Frisbee I II Foundation
Grant Healthcare Foundation
Key Food Stores Foundation, Inc.
KEYS
F.M. Kirby Foundation
Carmella Kramer
Jim and Dixie Kreider
Board and Staff, The Leukemia & Lymphoma Society, Northern California Chapter
Lewisville Memorial Hospital
Local 148 Operating Engineers
McCullough Foundation
Bob McKown Memorial Assoc.
Mercedes Benz Credit Corp.
Nokia
Notarfrancesco Memorial Golf Outing
Northwestern Mutual Life Foundation
Parents Against Leukemia
Ed & H Pillsbury Foundation
Prefered Health Systems

PricewaterhouseCoopers LLP
ProCuts
The Family of Ann Rodin
Sigma Alpha Epsilon Fraternity, University of Georgia
Robert Stifel Trust
Spear, Leeds & Kellogg
Mr. and Mrs. Gillis Thomas West Family
Xcelerate Corp.

Patient Services

$100,000-$499,999
Ortho Biotech
$50,000-$99,999
Amgen
Genentech
Novartis

$10,000-$49,999
The Stanley E. Brown Foundation
Canyon Springs Development
The Entertainment Industry Foundation
IDEC Milwaukee Foundation
New York State Department of Health at the request of Senator Charles J. Fuschillo, Jr.
Pall Corp.
Restaurant Concepts
SuperGen
Wyeth/Genetic Institute

Bone Marrow Drives

$10,000-$49,999
The Everhealth Foundation
F.M. Kirby Foundation
Milwaukee Foundation
The Perfect Match Golf Classic
Rotary International District 5130
Rotary International District 5170

Total Program

$100,000-$499,999
10th Annual San Antonio Golf Classic
Chase Manhattan Bank
CitiBank, NA
Rush Limbaugh

$50,000-$99,999
Cindy Crawford
Vesta Durbin
The Robert R. McCormick Tribune Foundation
Memorial Foundation, Inc.

$10,000-$49,999
Andrew Arthur
Auburn University/Panhellenic
The Sandra Atlas Bass and Edythe & Sol G. Atlas Fund
Alan Benaroya
Larry and Sherri Benaroya
Mr. and Mrs. Joe Besecker
Catherine Boshaw
James E. Bridges
The Florence and Arthur Brock Family Foundation
Scott Bruin
Mr. & Mrs. Joseph Bruno

Canyon Springs Development
Capital Group Companies
Carrs-Gottstein Foods/Safeway
Cell Therapeutics, Inc.
Central Texas Association of Bass Clubs
Dorothy M. Culbertson
Frances M. Day
O. Paul Decker Memorial Foundation
The Draper Foundation
Employee Community Fund of Boeing St. Louis
Marcel & Francine Gani
William and Nadine Gibson Family Foundation
Mark Grace Foundation
Heinz USA
The Hellis Foundation
Hewitt Family Foundation
Highmark BlueCross BlueShield
Margaret Ingold
The Dan Jansen Foundation, Inc.
Kate M. Kelley Foundation
Kentch Energy Systems, Inc.
Jack J. Kessler, Esq.
Mr. Sanjay Kumar
Mario Lemieux Foundation
Michael & Nicole Lincoln
Jeffrey & Ingrid Lion
The Marcus Family
Douglas Marshall
Mark E. Mason
Bruce Matthews
Mary Kay McCaw
The McCutchen Foundation
Mike McKernan
Microsoft
Michael Nash
Sheryl & Peter Neupert
The New York Community Trust
Tom and Cathy O’Keefe
Mr. & Mrs. Richard G. Post
Michael Rona
Sarver Charitable Foundation
Edith M. Schweckendiek Trusts
Scott Foundation
The Sidney, Milton & Leoma Simon Foundation
Phil and Sally Smart
Phil Smart, Inc.
Carmine Smeraldo
Speedway Children’s Charities
Garrett Stauffer, CPA
Todd Stottlemeyer
Michael Sweig
Robert & Jane Tschudy
University Sports Publications
Roseann Waindel Foundation
Wallmart
Charles B. Wang Foundation
WAWA Incorporated
Harry & Jeanette Weinberg Foundation, Inc.
Wells Fargo Bank
Mr. & Mrs. John C. Whetstone
Pamela Whorton
Stuart A. Williams, Esq.
Rod Woodson
Organizational Partnerships

Sponsorships

$500,000-$999,999
- Chase Manhattan Bank

$100,000-$499,999
- American Bicycle Association

$50,000-$99,999
- Anchor Bancorp, Inc.
- Bank of America
- Chrysler/Plymouth
- Cumberland Packing Corp./Sweet N Low

$10,000-$49,999
- Acorda South Florida
- Adobe Systems, Inc.
- Alaska Airlines
- Alliance Steel
- American Airlines
- American Investors
- Ameritech
- Andersen Consulting
- Peter & Georgia Angiello Foundation
- Anheuser-Busch
- Arnold & Porter
- Ascension Parish Leukemia/Cancer Fundraiser
- AT&T Foundation
- B & B Washington's Caterer
- Bag & Save Supermarkets
- Bank One
- BBDO Detroit, Inc.
- BellSouth Mobility
- Berlex Laboratories
- Bert Smith & Co.
- BET Holdings, Inc.
- Bitco Enterprises
- BlueCross BlueShield of California
- BlueCross BlueShield of Mississippi
- BlueCross BlueShield of New Jersey
- Bosweله Solutions
- BP Amoco
- Bristol Myers Squibb
- British Aerospace
- British Airways
- Brown & Wood LLP
- Butera Properties
- Campbell & Company
- Capital One
- Cinergy
- Clark/Bardes, Inc.
- Classic Auto Coupons
- Cleary, Gottlieb, Steen & Hamilton
- Cleveland Clinic
- Clipper Navigation
- Comcast
- Comerica Bank
- Computer Science Corporation
- Philip S. Contacos
- Corporate Express Business Interiors
- Costo Wholesale
- Couter Pharmaceuticals
- Robert Coury
- Credit Suisse/First Boston Corporation

$50,000-$99,999
- John and Shirley Davies
- Susan Davis International
- Deloitte & Touche
- Delta Airlines
- Deutsche Bank
- The Document Company - Xerox
- Dodge Different
- Donaldson, Lufkin & Jenrette
- Hardy & Hayes, John D. Bettes
- ELG Haniel Metals Corp.
- Emily Water Company
- EON, Inc.
- Ernst & Young, LLP
- Fannie Mae Foundation
- Fifth Third Bank
- Fight for Children
- Food Service Management, Dominic Abbott
- Foodland Independent Retailers
- The Ford Motor Company
- Freddie Mac
- FutureNext Consulting, Inc.
- The Gap
- GE Lighting
- Getz Foundation
- Gibson Musical Instruments
- Goldman Sachs & Co.
- Grubb & Ellis
- Gwinnett Place Honda
- Halliburton Energy Services
- Harris Bank
- Harris Beach Wilcox, LLP
- Harris Marketing Group
- Hershey Park Arena and Hockey
- The Hilton Washington
- Hoenig & Co., Inc.
- Freddie Hoffman
- Hoffman-La Roche
- IBM
- Icomix
- JMC, Inc.
- Infinity Outdoor
- International House of Pancakes
- J&K Medical Center
- Johnson & Johnson
- Johnson & Johnson Search America
- J.P. Morgan & Co.
- John Kellenyi
- Kemira Pigments, Inc.
- Key Bank
- Key Clubs of Central Pennsylvania
- Key Food Stores Foundation, Inc.
- Kirkland & Ellis
- Children of Maryanne & Henry J. Knott, Jr.
- Kojian Management Corporation
- KPMG LLP
- Lafarge Corp.
- Lake Stockton Yacht Club
- Lakeside Building Maintenance
- Larnamore Motor Corporation
- LaSalle Bank
- Theodore Lazzaro, D.M.D., M.D., LTD.
- Leiner Health Products/Your Life Vitamins
- Levi Strauss & Co.
- Liberty Media Holdings
- Litton PRC
- Lockheed Martin Global Telecommunications
- Logicon Incorporated, a Northrop Grumman Company
- Lunardi's Supermarkets
- Margaret McCarthy Foundation
- Marriott International
- Marsh USA, Inc.
- Massey Charitable Trust
- MBNA
- HBO
- Mitsubishi
- Montana State University
- Morgan Bank
- M & T Bank
- Mort & Co., Inc.
- Merrill Lynch
- Metabolic
- The Mills Corporation
- Montpellier Resources
- Morgan Keegan
- Morgan Stanley Dean Witter
- Mike Munchak
- National City Bank, Pennsylvania
- National Rural Utilities Cooperative Finance Corporation
- The Niello Company
- No Name Steaks
- North American Operations
- Oracle
- Ortho Biotech
- Pat Gallagher, PGT Trucking Inc.
- PepsiCo Foundation
- Pepsi-Cola
- Pfizer, Inc.
- Pharmacology Corporation
- Phi Gamma Delta Fraternity
- Planned Systems International, Inc.
- Plumbers & Pipefitters Local Union 72
- PNC Bank, Pittsburgh, PA
- Price Modern, Inc.
- PricewaterhouseCoopers LLP
- Provident Bank
- Putnam Allstate Advisor
- Reliant Energy
- Russell Reynolds Associates
- S&G Electric
- Safeco
- Salomon Smith Barney
- San Diego Chargers
- Schering Laboratories
- Servicemark Communications
- Shearman & Sterling
- The Sheakley Group of Companies
- Silicon Graphics
- Smart DM
- Smith-Cains
- Snyder Communications, Inc.
- Sonny's Real-Perp Bar-B-Q
- Sony Digital Audio Disc Corporation
- Southern Cultural Heritage Corporation
- Spear, Leeds & Kellogg
- Sprint PCS
- Star Acquisitions
- Steele Enterprises
- STX, Inc.
- Sullivan Papain Block McGrath Cannavo
- SuperValue, Pittsburgh, PA
- Sudler Cancer Center
- Talaf Motor Company
- Tesco
- Temptation
- Tenet Louisiana HealthSystem
- Robert E. Torray & Co. Inc.
- Travelers Express
- Tully's Coffee
- Turner Construction
- Ukorps
- University of Pittsburgh Medical Center
- UPMC Health Systems
- US Airways
- UUNET
- Valley Lexus
- Verizon Communications
- Virginia Oncology Association
- Wake Forest University
- Walt Disney Memorial Cancer Institute at Florida Hospital
- Washington Gas
- Waste Management
- Watson Wyatt Worldwide
- WB3 Charities Fund of Robert R.
- McCormick Tribune Foundation
- Welge, Gosnall & Manges LLP
- Weitz & Luxenberg
- Wells Fargo Bank
- Whittman-Hart
- WRO, Inc.
- Yellow Corporation

Promotions

$1,000,000 and above
- The Olive Garden Italian Restaurant
- DiabAlmeria Marketing

$500,000-$999,999
- KGO NewsTalk AM810

$100,000-$499,999
- Rhubarb Jones
- SCANA
- Sunflower Opera Company
- WYAY-FM Y106.7 Hit Country
- WBJZ Charities

$10,000-$49,999
- Adelphia Cable
- Azo, Inc.
- California-Nevada Operating Engineers
- Coastal Corporation
- Cohutta Water
- Cointar
- Hooters
- Houston Mercedes-Benz
- Infinity Broadcasting Corp.
- Jazzercise
- JNS Consulting Engineers, Inc.
- The Kroger Co.
- K2SN Radio
- Ladd-Hanford Chrysler-Plymouth-Dodge-Jeep-Mazda
- Mighty Taco
- Miller Brewing Company
- Music City 103
- Nashville Scene
- Northwest Airlines AirCare Services
- O'Charley's Inc.
- Outback Steakhouse
- Pennsylvania District Key Clubs
- Pennsylvania Physicians Care
- Realm Charity Golf
- The Regence Group
- BlueCross BlueShield of Oregon
- BlueCross BlueShield of Utah
- BlueCross BlueShield of Washington
- Regence Life & Health
- Joseph Ross Jewelers
- Safeway Stores, Inc.
- Saturn of Harrisburg
- Shults Ford
- SouthPark
- Thomas Sumter ACA Derby
- Timal Automotive Services
- Villa Pizza
- Volvo Cars of North America
- WBF8 Radio - The Bob & Tom Show
- WVBT
- WJYE-FM
- WZTV Fox 17
Report of independent auditors

Board of Trustees

The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated statement of financial position of The Leukemia & Lymphoma Society, Inc. (the Society) as of June 30, 2000, and the related statements of activities, cash flows and functional expenses for the year then ended. These consolidated financial statements are the responsibility of the Society's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. The prior year summarized comparative information has been derived from the Society's 1999 consolidated financial statements and, in our report dated September 30, 1999, we expressed an unqualified opinion on those statements.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2000, and the changes in its net assets and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

KPMG LLP

October 10, 2000
New York, New York
### Consolidated Statement of Financial Position

The Leukemia & Lymphoma Society, Inc.  
June 30, 2000 (with comparative amounts at June 30, 1999)  
in thousands

<table>
<thead>
<tr>
<th>Assets</th>
<th>2000</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$11,114</td>
<td>$22,385</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>1,034</td>
<td>1,158</td>
</tr>
<tr>
<td>Legacies and contributions receivable (note 2)</td>
<td>2,598</td>
<td>2,115</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>2,420</td>
<td>860</td>
</tr>
<tr>
<td>Investments, at fair value (note 3)</td>
<td>67,354</td>
<td>40,544</td>
</tr>
<tr>
<td>Equipment and leasehold improvements, less accumulated depreciation and amortization of $1,685 and $1,107</td>
<td>2,478</td>
<td>1,805</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$86,998</strong></td>
<td><strong>$68,867</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities and Net Assets</th>
<th>2000</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$7,642</td>
<td>$6,796</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>3,413</td>
<td>2,774</td>
</tr>
<tr>
<td>Grants payable (note 4)</td>
<td>34,256</td>
<td>26,015</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>45,311</strong></td>
<td><strong>35,585</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net assets:</th>
<th>2000</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>39,255</td>
<td>30,701</td>
</tr>
<tr>
<td>Temporarily restricted (note 7)</td>
<td>1,371</td>
<td>1,608</td>
</tr>
<tr>
<td>Permanently restricted (note 7)</td>
<td>1,061</td>
<td>973</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>41,687</strong></td>
<td><strong>33,282</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total liabilities and net assets</th>
<th>2000</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>$86,998</strong></td>
<td><strong>$68,867</strong></td>
<td></td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
Consolidated Statement of Activities

The Leukemia & Lymphoma Society, Inc.
Year ended June 30, 2000 (with comparative totals for the year ended June 30, 1999)
in thousands

<table>
<thead>
<tr>
<th>Temporary</th>
<th>Permanently</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>Restricted</td>
<td>Restricted</td>
</tr>
</tbody>
</table>

### Operating Revenue

<table>
<thead>
<tr>
<th>Description</th>
<th>2000</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campaign contributions</td>
<td>$151,858</td>
<td>$305</td>
</tr>
<tr>
<td>Less direct donor benefit costs</td>
<td>(28,258)</td>
<td>-</td>
</tr>
<tr>
<td>Net campaign contributions</td>
<td>123,600</td>
<td>305</td>
</tr>
<tr>
<td>Legacies</td>
<td>5,866</td>
<td>-</td>
</tr>
<tr>
<td>Net interest and dividend income (note 3)</td>
<td>2,007</td>
<td>19</td>
</tr>
<tr>
<td>Net appreciation in fair value of investments</td>
<td>653</td>
<td>103</td>
</tr>
<tr>
<td>Grant refunds</td>
<td>794</td>
<td>-</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>664</td>
<td>(664)</td>
</tr>
<tr>
<td><strong>Total operating revenue</strong></td>
<td><strong>133,584</strong></td>
<td><strong>(237)</strong></td>
</tr>
</tbody>
</table>

### Operating Expenses (note 8)

<table>
<thead>
<tr>
<th>Description</th>
<th>2000</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td>33,197</td>
<td>-</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>35,200</td>
<td>-</td>
</tr>
<tr>
<td>Public health education</td>
<td>20,987</td>
<td>-</td>
</tr>
<tr>
<td>Professional education</td>
<td>5,722</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td><strong>95,106</strong></td>
<td>-</td>
</tr>
<tr>
<td>Supporting Services:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and general</td>
<td>8,983</td>
<td>-</td>
</tr>
<tr>
<td>Fund raising</td>
<td>20,941</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td><strong>29,924</strong></td>
<td>-</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td><strong>125,030</strong></td>
<td>-</td>
</tr>
</tbody>
</table>

### Change in net assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2000</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in net assets</td>
<td>8,554</td>
<td>(237)</td>
</tr>
</tbody>
</table>

### Net Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2000</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning of year</td>
<td>30,701</td>
<td>1,608</td>
</tr>
<tr>
<td><strong>End of year</strong></td>
<td><strong>39,255</strong></td>
<td><strong>1,371</strong></td>
</tr>
<tr>
<td></td>
<td><strong>$41,687</strong></td>
<td><strong>$3,061</strong></td>
</tr>
</tbody>
</table>
Consolidated Statement of Cash Flows
The Leukemia & Lymphoma Society, Inc.
Year ended June 30, 2000 (with comparative amounts for the year ended June 30, 1999)
in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2000</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$8,405</td>
<td>$10,655</td>
</tr>
<tr>
<td><strong>Adjustments to reconcile change in net assets to net cash provided by operating activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net appreciation in fair value of investments</td>
<td>(756)</td>
<td>(1,047)</td>
</tr>
<tr>
<td>Permanently restricted campaign contributions</td>
<td>(88)</td>
<td>(580)</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>578</td>
<td>667</td>
</tr>
<tr>
<td><strong>Changes in assets and liabilities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decrease (increase) in accounts receivable</td>
<td>124</td>
<td>(667)</td>
</tr>
<tr>
<td>Increase in legacies and contributions receivable</td>
<td>(483)</td>
<td>(800)</td>
</tr>
<tr>
<td>Increase in prepaid expenses</td>
<td>(1,560)</td>
<td>(303)</td>
</tr>
<tr>
<td>Increase in accounts payable and accrued expenses</td>
<td>846</td>
<td>1,524</td>
</tr>
<tr>
<td>Increase in deferred revenue</td>
<td>639</td>
<td>776</td>
</tr>
<tr>
<td>Increase in grants payable</td>
<td>8,241</td>
<td>4,196</td>
</tr>
<tr>
<td><strong>Net cash provided by operating activities</strong></td>
<td>15,946</td>
<td>14,421</td>
</tr>
<tr>
<td><strong>Cash flows from investing activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchases of equipment and leasehold improvements</td>
<td>(1,251)</td>
<td>(938)</td>
</tr>
<tr>
<td>Purchases of investments, net</td>
<td>(26,054)</td>
<td>(6,388)</td>
</tr>
<tr>
<td><strong>Net cash used in investing activities</strong></td>
<td>(27,305)</td>
<td>(7,326)</td>
</tr>
<tr>
<td><strong>Cash flows from financing activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Permanently restricted campaign contributions</td>
<td>88</td>
<td>580</td>
</tr>
<tr>
<td><strong>Net cash provided by financing activities</strong></td>
<td>88</td>
<td>580</td>
</tr>
<tr>
<td><strong>Net (decrease) increase in cash and cash equivalents</strong></td>
<td>(11,271)</td>
<td>7,675</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of year</td>
<td>22,385</td>
<td>14,710</td>
</tr>
<tr>
<td><strong>Cash and cash equivalents at end of year</strong></td>
<td>$11,114</td>
<td>$22,385</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
## Fiscal year 2000 functional expenses

<table>
<thead>
<tr>
<th></th>
<th>Program Services</th>
<th>Supporting Services</th>
<th>Total</th>
<th>Direct donor benefit costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awards and grants .</td>
<td>$31,849</td>
<td>$ -</td>
<td>$ -</td>
<td>$ -</td>
</tr>
<tr>
<td>Financial aid to patients .</td>
<td>-</td>
<td>3,808</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Salaries ..............</td>
<td>249</td>
<td>12,752</td>
<td>6,251</td>
<td>2,251</td>
</tr>
<tr>
<td>Employee benefits and taxes (note 5) . . .</td>
<td>44</td>
<td>2,329</td>
<td>1,351</td>
<td>457</td>
</tr>
<tr>
<td>Occupancy (note 6) . . .</td>
<td>12</td>
<td>1,444</td>
<td>882</td>
<td>316</td>
</tr>
<tr>
<td>Insurance . . . . . . . .</td>
<td>4</td>
<td>105</td>
<td>73</td>
<td>20</td>
</tr>
<tr>
<td>Telephone . . . . . . . .</td>
<td>8</td>
<td>697</td>
<td>662</td>
<td>138</td>
</tr>
<tr>
<td>Travel . . . . . . . . . .</td>
<td>29</td>
<td>789</td>
<td>454</td>
<td>162</td>
</tr>
<tr>
<td>Printing and supplies . . .</td>
<td>252</td>
<td>4,731</td>
<td>4,195</td>
<td>832</td>
</tr>
<tr>
<td>Equipment rentals . . . . .</td>
<td>13</td>
<td>785</td>
<td>501</td>
<td>166</td>
</tr>
<tr>
<td>Postage and shipping . . . .</td>
<td>36</td>
<td>2,137</td>
<td>2,222</td>
<td>392</td>
</tr>
<tr>
<td>Meetings . . . . . . . . . .</td>
<td>142</td>
<td>1,458</td>
<td>697</td>
<td>253</td>
</tr>
<tr>
<td>Professional fees . . . .</td>
<td>530</td>
<td>3,274</td>
<td>3,148</td>
<td>541</td>
</tr>
<tr>
<td>Miscellaneous . . . . . .</td>
<td>23</td>
<td>683</td>
<td>412</td>
<td>152</td>
</tr>
<tr>
<td>Depreciation and amortization . . . . . . . .</td>
<td>6</td>
<td>208</td>
<td>139</td>
<td>42</td>
</tr>
<tr>
<td>Total expenses . . . . . .</td>
<td>$33,197</td>
<td>$35,200</td>
<td>$20,987</td>
<td>$5,722</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
1. Organization and Significant Accounting Policies

Organization
The Leukemia & Lymphoma Society, Inc. (formerly Leukemia Society of America, Inc.) (the "Society") is a national not-for-profit health agency dedicated to seeking the cause and eventual cure of leukemia, lymphoma, Hodgkin's disease and myeloma and improving the quality of life of patients and their families. The Society's principal activities, which are conducted through its local chapters and the Home Office, include awarding research grants; facilitating psychosocial support groups; providing financial aid to patients; answering phone requests for blood-related cancer information made to the Society's Information Resource Center; and disseminating educational information about blood-related cancers in the form of publications, internet sites and symposia sponsorship for both the medical community and the general public.

Tax-Exempt Status
The Society qualifies as a charitable organization as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, is exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since the Society is publicly-supported, contributions to the Society qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

Principles of Consolidation
The accompanying consolidated financial statements include the accounts of the Society, which encompasses the Home Office of the Society and its fifty-seven chapters, as well as its not-for-profit affiliates, Leukemia Society Research Programs, Inc. and Leukemia Society of America Research Foundation. All significant intercompany and intra-Society accounts and transactions have been eliminated in consolidation.

Net Asset Classifications
To ensure observance of limitations and restrictions placed on the use of resources available to the Society, funds that have similar characteristics have been classified into three net asset categories as follows:

- Unrestricted net assets: Consist of funds that are fully available, at the discretion of the Board of Trustees, for the Society to utilize in any of its programs or supporting services.
- Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific time period or purpose, as well as amounts relating to term endowment or deferred giving arrangements in which the funds must be maintained intact over the lifetimes of the donors.
- Permanently restricted net assets: Consist of funds that contain donor-imposed restrictions requiring that the principal be invested in perpetuity and that only the income be used. Income earned on these funds may be unrestricted or temporarily restricted, depending upon the donor-imposed restrictions.

Contributions and Deferred Revenue
Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions. Temporarily restricted contributions that are received and expended in the same period are reported as unrestricted contributions. Conditional contributions are recognized as revenue when the conditions have been substantially met. Deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year-end.

Donated Services
A substantial number of volunteers have made significant contributions of their time to help develop the Society's programs and activities. The value of such volunteer services has not been reflected in the accompanying consolidated financial statements as it does not meet the criteria for revenue recognition.

Cash Equivalents
Cash equivalents consist of money market accounts and short-term investments with a maturity of three months or less from date of purchase.

Equipment, Leasehold Improvements and Depreciation
Equipment and leasehold improvements are recorded at cost, if purchased, or at fair value at date of donation, if contributed, and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter.

Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires the Society's management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Summarized Financial Information
The financial statements are presented with 1999 comparative information. With respect to the statement of activities, such prior year information is not presented by net assets class and, in the statement of functional expenses, 1999 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with the Society's 1999 financial statements from which the summarized information was derived.

2. Legacies and Contributions Receivable
The Society's legacies and contributions receivable at June 30, 2000 and 1999 consist of unconditional promises to give, primarily in the form of legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Amounts are scheduled to be received as follows (in thousands):

<table>
<thead>
<tr>
<th>Description</th>
<th>2000</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>$ 2,351</td>
<td>$ 1,868</td>
</tr>
<tr>
<td>After 5 years</td>
<td>353</td>
<td>353</td>
</tr>
<tr>
<td>Total</td>
<td>$ 2,704</td>
<td>$ 2,221</td>
</tr>
<tr>
<td>Less discount to present value</td>
<td>(106)</td>
<td>(106)</td>
</tr>
<tr>
<td>Total</td>
<td>$ 2,598</td>
<td>$ 2,115</td>
</tr>
</tbody>
</table>
3. Investments

The following is a summary of investments at June 30, 2000 and 1999 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2000</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds</td>
<td>$35,325</td>
<td>$14,552</td>
</tr>
<tr>
<td></td>
<td>$35,325</td>
<td>$14,552</td>
</tr>
<tr>
<td>Corporate notes and bonds</td>
<td>14,099</td>
<td>15,108</td>
</tr>
<tr>
<td></td>
<td>14,209</td>
<td>15,074</td>
</tr>
<tr>
<td>Common stocks and mutual funds</td>
<td>15,311</td>
<td>7,855</td>
</tr>
<tr>
<td></td>
<td>17,200</td>
<td>9,259</td>
</tr>
<tr>
<td>U.S. Government obligations</td>
<td>558</td>
<td>1,609</td>
</tr>
<tr>
<td></td>
<td>562</td>
<td>1,601</td>
</tr>
<tr>
<td>Other</td>
<td>58</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>58</td>
<td>58</td>
</tr>
<tr>
<td>Total</td>
<td>$65,351</td>
<td>$39,182</td>
</tr>
<tr>
<td></td>
<td>$67,354</td>
<td>$40,544</td>
</tr>
</tbody>
</table>

Debt and equity securities are recorded at fair value as determined by quoted market prices. Mutual funds are recorded at fair value using published unit values. Investment expenses of $172,000 and $132,000 have been netted against interest and dividend income for the years ended June 30, 2000 and 1999, respectively.

4. Awards and Grants

Awards and grants for research are recognized as expense in the year approved by the Society's Board of Trustees. Multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of the Society's Board of Trustees. In addition to unconditional grants payable of $34,256,000 at June 30, 2000, the Society has grant commitments of $52,344,000 that are conditioned upon future events.

The Society has announced the creation of a major new research program entitled Specialized Centers of Research (“SCOR”). In fiscal 2000, three of these five-year grants, each providing support of up to $1,500,000 per year and subject to annual review, were awarded to cross-disciplinary research teams based on a competitive review of applications by the Society’s Medical and Scientific Committee.

5. Pension Plan

The Society has a noncontributory, defined contribution 403(b) pension plan covering all employees meeting age and service requirements. Contributions are based on a percentage of each eligible employee’s salary and years of service. In fiscal 2000, following a study of pension benefits provided by peer and other organizations, the Society enhanced its plan. Expense under this plan aggregated $1,181,000 and $694,000 for the years ended June 30, 2000 and 1999, respectively.

6. Occupancy Expense and Lease Commitments

The leases for premises which the Society’s Home Office and chapters occupy expire on various dates through June 30, 2010 and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses and utilities.

In July 2000, the Society moved its Home Office from midtown Manhattan to White Plains, New York, and entered into a ten year lease. Fiscal 1999 occupancy expense includes $700,000 related to the early termination of the New York City lease.

The approximate minimum future annual rental commitments, are summarized as follows (in thousands):

<table>
<thead>
<tr>
<th>Year ended June 30:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
</tr>
<tr>
<td>2002</td>
</tr>
<tr>
<td>2003</td>
</tr>
<tr>
<td>2004</td>
</tr>
<tr>
<td>2005</td>
</tr>
<tr>
<td>Thereafter</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

7. Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets were available for the following purposes at June 30, 2000 and 1999 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2000</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research program</td>
<td>$605</td>
<td>$1,017</td>
</tr>
<tr>
<td>Patient service and bone marrow donor programs</td>
<td>374</td>
<td>653</td>
</tr>
<tr>
<td>Professional education program</td>
<td>50</td>
<td>40</td>
</tr>
<tr>
<td>Other programs</td>
<td>342</td>
<td>287</td>
</tr>
<tr>
<td>Total</td>
<td>$1,371</td>
<td>$1,608</td>
</tr>
<tr>
<td></td>
<td>$1,061</td>
<td>$973</td>
</tr>
</tbody>
</table>

8. Joint Costs Allocation

In 2000 and 1999, the Society incurred joint costs for informational materials and activities that included fund raising appeals as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2000</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund raising</td>
<td>$9,332</td>
<td>$6,203</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>1,315</td>
<td>1,090</td>
</tr>
<tr>
<td>Public health education</td>
<td>4,539</td>
<td>3,591</td>
</tr>
<tr>
<td>Total</td>
<td>$15,186</td>
<td>$10,884</td>
</tr>
</tbody>
</table>

In fiscal 2000, the Society adopted the provisions of AICPA Statement of Position (SOP) 98-2, “Accounting for Costs of Activities of Not-for-Profit Organizations and State and Local Government Entities That Include Fund Raising.” Since the Society continued to meet the criteria for allocation, the new SOP had no significant effect.
National leaders

**Chairman of the Board**
Jay L. Silver
Sugar Land, TX

**Vice Chairman**
Peter J. Quesenberry, MD
Professor of Medicine
Boston University (appointment pending)
Director of Research
Roger Williams Hospital
Providence, RI

**Vice Chairman for Medical and Scientific Affairs**
W. Stratford May, Jr., MD, PhD
Director
Shands Cancer Center, University of Florida
Gainesville, FL

**Secretary/Treasurer**
Richard A. Fess
President
MidFlorida Agencies of Orlando, Inc.
Longwood, FL

**National Board of Trustees**
Bruce H. Allen
Vice President
SunTrust Bank
Delray Beach, FL

Fay Allen
State Farm Insurance
Jeffersonville, IN

Scott W. Allison
Senior Vice President
Connors Communications
San Francisco, CA

Stephen M. Bailey
Attorney-at-Law
Littleton, CO

Irwin D. Bernstein, MD
Program Head, Pediatric Oncology Program
Fred Hutchinson Cancer Research Center
Seattle, WA

Joseph E. Beseker
Chairman, President, and CEO
Emerald Asset Management
Lancaster, PA

Janis L. Biermann, MS
Director, National Folic Acid Campaign
March of Dimes Birth Defects Foundation
White Plains, NY

Alexandra Mayes Birnbaum
New York, NY

M. O. Breeding
Oklahoma City, OK

Wilburn Brewer, Jr.
Partner
Nexsen Pruet Jacobs & Pollard, LLP
Columbia, SC

Paul Calabrese, MD
Chairman Emeritus, Department of Medicine
Brown University School of Medicine
Rhode Island Hospital
Providence, RI

Kathryn L. Calame, PhD
Department of Microbiology
College of Physicians and Surgeons
Columbia University
New York, NY

Robert A. “Spider” Cantley
The Insulation Co.
Fremont, CA

John M. Coffin, PhD
Professor of Microbiology
Tufts University School of Medicine
Boston, MA

Michael Copley
Vice Chairman, Board of Trustees
Children's Hospital Foundation
San Diego, CA

James Cox
President
Dallas Mechanical Air Systems
Dallas, TX

Kathryn C. Danella
Vice President and General Manager
Boca Pointe Community Association, Inc.
Boca Raton, FL

David S. Dimling
Board of Advisors
Equity Capital Partners, Inc.
Atlanta, GA

Cynthia M. Driscoll
Finance Manager
Women & Infants Hospital of Rhode Island
Providence, RI

Terri S. Edlund
Vice President
Bank of America
San Antonio, TX

Lawrence D. Ellis, MD
Professor of Medicine
University of Pittsburgh
Pittsburgh, PA

Stephen G. Emerson, MD, PhD
Chief, Hematology-Oncology
University of Pennsylvania School of Medicine
Philadelphia, PA

Richard C. Ficken
Dirx, Ficken & Associates, Inc.
Eden Prairie, MN

Thomas L. Fitzpatrick
Manager of Corporate Credit
Saint Gobain Corporation
Worcester, MA

Frances M. Fox, RN, MSN
Certified School Nurse
Mt. Laurel, NJ

Paul N. Frimmer
Inell & Mandella LLP
Los Angeles, CA

Christine K. Frisbee
New Canaan, CT

Richard Garrison
President and Owner
Advertising Novelty Co., Inc.
Washington, DC

John A. Geoghegan
Gelliart and Cutler, PC
Purhace, NY

Alan M. Gewirtz, MD
Stern Cell Biology and Therapeutic Program
University of Pennsylvania School of Medicine
Philadelphia, PA

Paul G. Glaab
Laguna Niguel, CA

Keith P. Harenda
President/Owner
KPH Construction, Corp.
Waukesha, WI

Kathleen Hays, RN, MN
Director, Inpatient Oncology Services
University of Pittsburgh Cancer Institute
University of Pittsburgh Medical Center
Pittsburgh, PA

Patrick J. Healy, PhD
Senior Vice President
Finance and Administration
Quinnipiac College
Hamden, CT

Gary D. Hirsch
Chairman
Elk Capital, LLC
Rye, NY

Lynn C. Hoover
Morrison & Hecker, LLP
Kansas City, MO

Anthony L. Huffman
President/Owner
Huffman & Company, CPA
Jackson, MS

Thomas F. Hunter
President & CEO
Frequency Marketing, Inc.
Milford, OH

William Iannìelli
President
Professional Painting, Inc.
New Haven, CT

Anne K. Johnson
Senior Lending Officer
CTX Mortgage
Sarasota, FL

Dan J. Jordanger
Partner
Hunton & Williams
Richmond, VA

John M. Kamins
Partner
Honigman Miller Schwartz and Cohn
Detroit, MI

Judith E. Karp, MD
Professor of Medicine
Greenebaum Cancer Center
University of Maryland Medical Systems
Baltimore, MD

Virginia Lee Kintz
Master Long Term Care Representative
GE Financial Assurance
Schoharie, NY

Leslie Elliot Krause, Esq.
Krause & Krause
New York, NY

William S. Lear
Chief Financial Officer
BioSafe Medical Technologies, Inc.
Chicago, IL

Diana Lee
Wichita, KS

Lynna M. Lesko, MD, PhD
Senior Associate Director
International Clinical Research
General Medicine Division
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT

Michael W. Long, PhD
Professor, Department of Pediatrics
Member, Comprehensive Cancer Center
University of Michigan Medical Center
Ann Arbor, MI

Pasquale M. Lovascio
Huntington Station, NY

Mark E. Mason
Vice Chairman
Oxford Development Company
Pittsburgh, PA

Catherine M. Mattson
Market Development Manager
Hewlett Packard
Roseville, CA

Ronald P. McCaffrey, MD
Director, The Cancer Center
Lowell General Hospital
Lowell, MA

Thomas R. McDonald
Tucson, AZ

John R. Mohr
President
JRM Communications
Cold Spring Harbor, NY
Senior staff

Dennis F. Moore, MD, FACP
Chairman, Department of Hematology-Medical Oncology
Wichita Clinic, PA
Wichita, KS

Virginia S. Morris
Medina, WA

Suzanne J. Muntzing
Wealth Management Specialist
Wells Fargo
San Francisco, CA

Rodman N. Myers
Of Counsel
Honigman Miller Schwartz and Cohn
Detroit, MI

Judge Robert H. Newman
Miami Beach, FL

Andrew E. Nolan
Partner
PricewaterhouseCoopers LLP
New York, NY

Mary J. Oyer
Northfield, IL

Dominic Pino
Partner
PricewaterhouseCoopers LLP
Ft. Lauderdale, FL

David G. Poplack, MD
Director
Texas Children’s Cancer Center
Houston, TX

David B. Quinty
Senior Resident Vice President
Merrill Lynch
Birmingham, AL

Martin Rauch
Owner
RE/MAX Schoolside REALTORS
Cheshire, CT

William H. Reimers
Regional Sales Manager
Bowman Enterprises, Inc.
Jacksonville, NC

Marcie Rehman Rogel
Community Education
Children’s Hospital
Columbus, OH

Naomi Rosenberg, PhD
Professor
Tufts University School of Medicine
Boston, MA

Kevin R. Ryan
Yampolsky, Mandeloff, Silver & Co.
Philadelphia, PA

Donald H. Salsbery
Director of Finance
UFCW
Washington, DC

Thomas J. Scanlon
Managing Partner
Donahue & Scanlon
Cleveland, OH

Rhonda Sheakley
Cincinnati, OH

Frank T. Short
Government Services Director
Leagre Chandler and Millard
Indianapolis, IN

Norbert J. Sieber
Executive Vice President
MARC Advertising
Pittsburgh, PA

Kay H. Singer, PhD
Assistant Dean
Duke University
Durham, NC

Thomas R. Snyder
First Vice President
SunTrust Bank, Nashville, NA
Nashville, TN

James E. Sparkes
Managing Partner, Syracuse
Harris Beach & Wilcox, LLP
Syracuse, NY

Grant E. Stebner
Tigard, OR

Jeffrey H. Trenton
President
Proficiency Capital Corporation
Los Angeles, CA

Joseph D. Verdirame, MD
Hematology & Oncology Consultants, PC
Omaha, NE

William M. Ward, Jr.
President and CEO
Presbyterian Manors of Mid-America
Wichita, KS

Owen N. Witte, MD
David Saxon Presidential Chair
in Developmental Immunology
Howard Hughes Medical Institute/UCLA
Los Angeles, CA

Judge Robert M. Yacobi
Williamsburg, VA

Joseph Yurfest
CWF Project Director
CareFirst Blue Cross Blue Shield
Timonium, MD

Dwayne Howell
President and CEO

Research & Medical Programs
Marshall A. Lichtman, MD
Executive Vice President
Research & Medical Programs

Alan Kinniburgh, PhD
Vice President
Research Administration

Revenue Development
Richard J. Geswell
Senior Vice President
Revenue Development

Greg Effers
Vice President
Campaign Development

Finance/Information Technology
John Walter
Senior Vice President
Finance & Information Technology

Jimmy Nangle
Vice President & Controller
Finance

Stephen B. Lucas
Chief Information Officer

Government & Legislative Affairs
George Dahlman
Vice President
Public Policy

Marketing & Communications
Robert K. Wehrmann
Senior Vice President
Marketing & Strategy Development

Michael F. Aldrich
Vice President
Marketing and Product Development

Kenneth R. Lightcap
Vice President
Communications

Patient Services
Robin Kornhaber, MSW
Vice President
Patient Services
<table>
<thead>
<tr>
<th>State</th>
<th>Chapter Office Address</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alabama</td>
<td>100 Chase Park South, Suite 220, Birmingham, AL 35244</td>
<td>Phone: (205) 989-0098</td>
</tr>
<tr>
<td>Arizona</td>
<td>Desert Mountain States Chapter, 2990 E. Northern Avenue, E-100, Phoenix, AZ 85028</td>
<td>Phone: (602) 788-8622</td>
</tr>
<tr>
<td>California</td>
<td>Greater Los Angeles Chapter, 100 Corporate Pointe, Suite 180, Culver City, CA 90230</td>
<td>Phone: (310) 348-5721</td>
</tr>
<tr>
<td>Delaware</td>
<td>100 West 10th Street, Suite 209, Wilmington, DE 19801</td>
<td>Phone: (302) 661-7300</td>
</tr>
<tr>
<td>District of Columbia</td>
<td>National Capital Area Chapter, 5845 Richmond Highway, Suite 630, Alexandria, VA 22303</td>
<td>Phone: (703) 960-1100</td>
</tr>
<tr>
<td>Florida</td>
<td>Central Florida Chapter, 3319 Maguire Blvd., Suite 101, Orlando, FL 32803</td>
<td>Phone: (407) 896-0733</td>
</tr>
<tr>
<td>Georgia</td>
<td>Georgia Chapter, 2625 Cumberland Parkway, Suite 205, Atlanta, GA 30339</td>
<td>Phone: (770) 438-6006</td>
</tr>
<tr>
<td>Illinois</td>
<td>Illinois Chapter, 100 W. Monroe, Suite 1610, Chicago, IL 60603</td>
<td>Phone: (312) 726-0003</td>
</tr>
<tr>
<td>Indiana</td>
<td>Indiana Chapter, 921 E. 86th Street, Suite 205, Indianapolis, IN 46240</td>
<td>Phone: (317) 726-2270</td>
</tr>
<tr>
<td>Kansas</td>
<td>Kansas Chapter, 555 N. Woodlawn, Bldg. 1, Suite 113, Wichita, KS 67208</td>
<td>Phone: (316) 687-2222</td>
</tr>
<tr>
<td>Kentucky</td>
<td>Kentucky Chapter, 710 West Main Street, Suite 201, Louisville, KY 40202-2690</td>
<td>Phone: (502) 584-8490</td>
</tr>
<tr>
<td>Louisiana</td>
<td>Louisiana Chapter, 3636 South i-10 Service Rd., Suite 304, Metairie, LA 70001</td>
<td>Phone: (504) 837-0945</td>
</tr>
<tr>
<td>Maryland</td>
<td>Maryland Chapter, 8600 LaSalie Road, Chester Building, Suite 314, Baltimore, MD 21206-2011</td>
<td>Phone: (410) 825-2500</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>Massachusetts Chapter, 495 Old Connecticut Path, Suite 220, Framingham, MA 01701-4567</td>
<td>Phone: (508) 879-5083</td>
</tr>
<tr>
<td>Michigan</td>
<td>Michigan Chapter, 1421 E. Twelve Mile Road, Bldg. A, Madison Heights, MI 48071</td>
<td>Phone: (248) 582-2900</td>
</tr>
<tr>
<td>Minnesota</td>
<td>Minnesota Chapter, 5217 Wayzata Blvd., Suite 221, St. Louis Park, MN 55416</td>
<td>Phone: (612) 545-3309</td>
</tr>
<tr>
<td>Mississippi</td>
<td>Mississippi Chapter, 405 Fontaine Place, Suite 103, Ridgeland, MS 39157</td>
<td>Phone: (601) 956-7447</td>
</tr>
<tr>
<td>Missouri</td>
<td>The Gateway Chapter, 77 West Port Plaza, Suite 101, St. Louis, MO 63146-3111</td>
<td>Phone: (314) 879-0780</td>
</tr>
<tr>
<td>Nebraska</td>
<td>Nebraska Chapter, 2665 Farnam Street, Omaha, NE 68131</td>
<td>Phone: (402) 344-2242</td>
</tr>
<tr>
<td>New Mexico</td>
<td>New Mexico Chapter, 3150 Carlisle, N.E., Suite 35, Albuquerque, NM 87110</td>
<td>Phone: (505) 830-6640</td>
</tr>
<tr>
<td>New York</td>
<td>Central New York Chapter, Learbury Centre, 401 N. Salina Street, Syracuse, NY 13203-1770</td>
<td>Phone: (315) 471-1050</td>
</tr>
<tr>
<td>Ohio</td>
<td>Central Ohio Chapter, Fourth and Race Towers, 105 West Fourth Street, Suite 900, Cincinnati, OH 45202</td>
<td>Phone: (513) 361-2100</td>
</tr>
<tr>
<td>Oklahoma</td>
<td>Oklahoma Chapter, 3613 N.W. 56th Street, Suite 230, Oklahoma City, OK 73112-4520</td>
<td>Phone: (405) 943-8888</td>
</tr>
</tbody>
</table>
Oregon
Oregon Chapter
6501 S.W. Macadam Avenue
Portland, OR 97201
Phone: (503) 245-9866

Pennsylvania
Central Pennsylvania Chapter
800 Corporate Circle, Suite 100
Harrisburg, PA 17110
Phone: (717) 652-6520

Eastern Pennsylvania Chapter
2401 Pennsylvania Avenue, Suite 2-D-1
Philadelphia, PA 19130
Phone: (215) 232-1100

Western Pennsylvania & West Virginia Chapter
Two Gateway Center, 13 North
Pittsburgh, PA 15222
Phone: (412) 395-2873

Rhode Island
Rhode Island Chapter
75 Sockanosset Crossroad
Suite 206 - Box 8099
Cranston, RI 02920
Phone: (401) 943-8888

South Carolina
South Carolina Chapter
1247 Lake Murray Boulevard
Irmo, SC 29063
Phone: (803) 749-4299

Tennessee
Tennessee Chapter
446 Metroplex Drive, Suite A-200
Nashville, TN 37211-3139
Phone: (615) 331-2980

Texas
North Texas Chapter
12850 Spurling Drive, Suite 190
Dallas, TX 75230
Phone: (972) 239-0959

South/West Texas Chapter
950 Isom Road, Suite 104
San Antonio, TX 78216
Phone: (210) 377-1775

Texas Gulf Coast Chapter
10777 N.W. Freeway, Suite 600
Houston, TX 77092
Phone: (713) 680-8088

Virginia
Virginia Chapter
2101 Executive Drive, Tower Box 21
Hampton, VA 23666
Phone: (757) 838-9351
Helping the Society through effective personal financial planning

There are several convenient ways you can direct your personal financial plans to support the fight against blood-related cancers:

• Include The Leukemia & Lymphoma Society in your will and leave a lasting legacy. You can direct gifts to be made in a specific amount, a percentage of your estate, or the remainder of your estate.

• Include The Leukemia & Lymphoma Society in your estate plans, and become a member of The Legacy Circle. Members receive regular updates on the progress being made in the fight against blood-related cancers and are invited to attend meetings with researchers.

• Consult with The Leukemia & Lymphoma Society to find out the best way to use your trust, insurance policy or other estate planning technique in the fight against blood-related cancers.

For more information, contact the Society's National Director of Planned Giving at 1.800.773.9958.
Contact
1311 Mamaroneck Avenue
White Plains, NY 10605
Tel: 914.949.5213
Fax: 914.949.6691
www.leukemia-lymphoma.org